Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | The Innovation |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666675823000899 |
| _version_ | 1797790828836421632 |
|---|---|
| author | Luxiang Wang Chunli Zhang Shuang Fan Xiaodong Mo Xiaoxia Hu |
| author_facet | Luxiang Wang Chunli Zhang Shuang Fan Xiaodong Mo Xiaoxia Hu |
| author_sort | Luxiang Wang |
| collection | DOAJ |
| first_indexed | 2024-03-13T02:10:05Z |
| format | Article |
| id | doaj.art-673107f1dc2a4b2ca0d3889c6153d1fb |
| institution | Directory Open Access Journal |
| issn | 2666-6758 |
| language | English |
| last_indexed | 2024-03-13T02:10:05Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Innovation |
| spelling | doaj.art-673107f1dc2a4b2ca0d3889c6153d1fb2023-07-01T04:35:49ZengElsevierThe Innovation2666-67582023-07-0144100461Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?Luxiang Wang0Chunli Zhang1Shuang Fan2Xiaodong Mo3Xiaoxia Hu4Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China; Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China; Corresponding authorShanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China; Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Corresponding authorhttp://www.sciencedirect.com/science/article/pii/S2666675823000899 |
| spellingShingle | Luxiang Wang Chunli Zhang Shuang Fan Xiaodong Mo Xiaoxia Hu Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? The Innovation |
| title | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_full | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_fullStr | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_full_unstemmed | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_short | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_sort | treatment options for adult intermediate risk aml patients in cr1 allo hsct or chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2666675823000899 |
| work_keys_str_mv | AT luxiangwang treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT chunlizhang treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT shuangfan treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT xiaodongmo treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT xiaoxiahu treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy |